GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Medicus Pharma Ltd (OTCPK:MDPLF) » Definitions » Tax Provision

Medicus Pharma (Medicus Pharma) Tax Provision : $0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Medicus Pharma Tax Provision?

Medicus Pharma's tax provision for the three months ended in Dec. 2023 was $0.00 Mil. Its tax provision for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.


Medicus Pharma Tax Provision Historical Data

The historical data trend for Medicus Pharma's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medicus Pharma Tax Provision Chart

Medicus Pharma Annual Data
Trend Dec21 Dec22 Dec23
Tax Provision
- - -

Medicus Pharma Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Tax Provision Get a 7-Day Free Trial Premium Member Only - - - - -

Medicus Pharma Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medicus Pharma (Medicus Pharma) Business Description

Comparable Companies
Traded in Other Exchanges
Address
100 King Street West, Suite 3400, One First Canadian Place, Toronto, ON, CAN, M5X 1A4
Medicus Pharma Ltd will carry on the business of pharmaceutical drug development focused initially on SkinJect. The objective of SkinJect is developing and commercializing novel microneedle arrays for the purpose of treating certain skin cancers, initially basal cell carcinoma.

Medicus Pharma (Medicus Pharma) Headlines

From GuruFocus

Medicus Pharma Opens the Market

By PRNewswire 10-26-2023